Results 81 to 90 of about 7,935 (218)

Immunomodulatory therapy in paediatric inflammatory bowel disease

Zdravniški Vestnik, 2013
Immunomodulatory drugs are indispensable in the treatment of children with both Crohn’s disease and ulcerative colitis, especially in maintaining remission.
András Arató
doaj  

Association between thiopurine medication exposure and Alzheimer's disease among a cohort of patients with inflammatory bowel disease

Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2019
Introduction Ras‐related C3 botulinum toxin substrate 1 (Rac1), a member of the Rho‐GTPase family of proteins, could be an Alzheimer's disease (AD) triggering co‐factor due to its effect on both amyloid precursor protein (APP) and tau.
S.Scott Sutton, Joseph Magagnoli, Tammy Cummings, James W. Hardin   +3 more
doaj   +1 more source

Hair loss in pediatric inflammatory bowel disease: Clinical recognition and implications for care

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Angela Anaeme, Liza Siegel, Meryl Perlman   +2 more
wiley   +1 more source

Shifts in Mucosa‐Associated Microbiota Reflect Inflammation Gradient in Postoperative Crohn's Disease

JCC Plus, Volume 1, Issue 5, September 2026.
ABSTRACT Emerging evidence suggests that mucosa‐associated microbiota play an important role in postoperative Crohn's disease recurrence after ileocecal resection, with bacterial and fungal communities shifting across disease trajectory. This Y‐ECCO literature review discusses these changes across the Rutgeerts inflammatory spectrum, supporting the ...
Maya Fischman
wiley   +1 more source

Successful allo‐hematopoietic stem cell transplantation using washed hematopoietic stem cells in a pediatric patient complicated by acute myeloid leukemia and severe anaphylaxis to blood product

Pediatric Investigation, EarlyView.
Jieyu Tian, Guanghua Zhu, Maoquan Qin, Chenguang Jia, Shuxuan Ma, Bin Wang, Yanhui Luo   +6 more
wiley   +1 more source

Comparative Effectiveness Analysis of Phase 3 Clinical Trials in Moderately to Severely Active Inflammatory Bowel Disease Reveals Increased Harm From Placebo and Challenges Equipoise

JCC Plus, Volume 1, Issue 5, September 2026.
Across 47 Phase 3 trials in Crohn's disease and ulcerative colitis, placebo exposure was associated with measurable harm. Disease exacerbation events showed the greatest excess risk, with one additional exacerbation occurring for every 8–13 patients assigned to placebo rather than active therapy.
Joëlle St‐Pierre, Zachary D. Fine, Evan N. Fear, Jeremy A. Klein, Natalie K. Choi, David T. Rubin   +5 more
wiley   +1 more source

Efficacy of Interleukin‐12/23 and Interleukin‐23 Inhibitors for Moderately to Severely Active Crohn's Disease in Advanced Treatment Failure Populations: Systematic Review and Network Meta‐Analysis

JCC Plus, Volume 1, Issue 5, September 2026.
ABSTRACT Background and Aims Earlier trials of advanced treatments indicated for moderately to severely active Crohn's disease used predominantly re‐randomized induction responder designs, whereas newer treatments were evaluated using treat‐through designs.
Christopher Ma, Marla Dubinsky, Gil Y. Melmed, Namita Joshi, Jenny Griffith, Fernando Aponte, Brooke Kim, Eric B. Collins, Kristen Westerhoff, Remo Panaccione   +9 more
wiley   +1 more source

Thiopurines and myeloid disorders: is more caution needed when treating inflammatory bowel disease patients?

, 2014
International audienceThiopurines remain the backbone therapy of inflammatory bowel diseases (IBD). However, these drugs have potential mutagenic and carcinogenic effects, especially when prescribed for a long time.
Beaugerie, Laurent, Lopez, Anthony, Peyrin-Biroulet, Laurent   +2 more
core   +1 more source

How Long Should We Taper Corticosteroids in Ulcerative Colitis? Insights From a Randomised Controlled Trial

JCC Plus, Volume 1, Issue 5, September 2026.
ABSTRACT Despite the widespread adoption of steroid‐sparing strategies, corticosteroids remain a cornerstone of induction therapy for moderate‐to‐severe ulcerative colitis (UC), yet the optimal tapering strategy remains poorly defined. This Y‐ECCO literature review summarises the randomised controlled trial by Kumar et al., which investigated the ...
Laura Gianolio
wiley   +1 more source

Klebsiella pneumoniae contributes to altered cytotoxicity of thiopurines in vitro: Possible implications of biotransformation and bacterial metabolism [PDF]

Background and purpose: Thiopurines are used in paediatric inflammatory bowel disease (IBD), but some patients do not respond. Because the gut microbiota influences drug efficacy and IBD-patient microbiota presents increased bacterial abundance, we ...
Bramuzzo, Matteo, Bellich, Barbara, Lagatolla, Cristina, Forgiarini, Sofia Sindici, Hofmann, Ute, Schaeffeler, Elke, Stocco, Gabriele, Franzin, Martina, Schwab, Matthias, Comar, Manola, Neef, Sylvia Karin, Decorti, Giuliana, Lucafò, Marianna, Haag, Mathias   +13 more
core   +1 more source